These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10354964)

  • 21. Assessment of 6-sulfatoxymelatonin rhythms and melatonin response to light in disease states: lessons from cirrhosis.
    Montagnese S; Middleton B; Corrias M; Mani AR; Skene DJ; Morgan MY
    Chronobiol Int; 2015 Mar; 32(2):187-94. PubMed ID: 25264562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men.
    Luboshitzky R; Levi M; Shen-Orr Z; Blumenfeld Z; Herer P; Lavie P
    Hum Reprod; 2000 Jan; 15(1):60-5. PubMed ID: 10611189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
    Otmani S; Demazières A; Staner C; Jacob N; Nir T; Zisapel N; Staner L
    Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems.
    Priano L; Esposti D; Esposti R; Castagna G; De Medici C; Fraschini F; Gasco MR; Mauro A
    J Nanosci Nanotechnol; 2007 Oct; 7(10):3596-601. PubMed ID: 18330178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased bioavailability of oral melatonin after fluvoxamine coadministration.
    Härtter S; Grözinger M; Weigmann H; Röschke J; Hiemke C
    Clin Pharmacol Ther; 2000 Jan; 67(1):1-6. PubMed ID: 10668847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
    Sathyan G; Xu E; Thipphawong J; Gupta SK
    BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs.
    Dawson D; Rogers NL; van den Heuvel CJ; Kennaway DJ; Lushington K
    J Biol Rhythms; 1998 Dec; 13(6):532-8. PubMed ID: 9850013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seasonal, menstrual and circadian secretions of melatonin, gonadotropins and prolactin in women.
    Kivelä A; Kauppila A; Ylöstalo P; Vakkuri O; Leppäluoto J
    Acta Physiol Scand; 1988 Mar; 132(3):321-7. PubMed ID: 3147572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin.
    Bénès L; Claustrat B; Horrière F; Geoffriau M; Konsil J; Parrott KA; DeGrande G; McQuinn RL; Ayres JW
    J Pharm Sci; 1997 Oct; 86(10):1115-9. PubMed ID: 9344167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin.
    Piérard C; Beaumont M; Enslen M; Chauffard F; Tan DX; Reiter RJ; Fontan A; French J; Coste O; Lagarde D
    Eur J Appl Physiol; 2001 Jul; 85(1-2):144-50. PubMed ID: 11513308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin.
    Fourtillan JB; Brisson AM; Gobin P; Ingrand I; Decourt JP; Girault J
    Biopharm Drug Dispos; 2000 Jan; 21(1):15-22. PubMed ID: 11038434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Safety of Intravenous, Intravesical, Rectal, Transdermal, and Vaginal Melatonin in Healthy Female Volunteers: A Cross-Over Study.
    Zetner D; Andersen LPK; Alder R; Jessen ML; Tolstrup A; Rosenberg J
    Pharmacology; 2021; 106(3-4):169-176. PubMed ID: 32937627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melatonin Bioavailability After Oral Administration of a New Delayed-Release Form in Healthy Male Volunteers.
    Ait Abdellah S; Gal C; Guinobert I; Bardot V; Raverot V; Vitacca A; Blondeau C; Claustrat B
    Drugs R D; 2024 Sep; 24(3):415-423. PubMed ID: 39174857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration.
    Warrington SJ; Barclay SP; John VA; Shotton PA; Wardle HM; Good W
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):219S-224S. PubMed ID: 4005126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients.
    Bellapart J; Roberts JA; Appadurai V; Wallis SC; Nuñez-Nuñez M; Boots RJ
    Clin Chem Lab Med; 2016 Mar; 54(3):467-72. PubMed ID: 26351927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K; Pechstein B; Schueler A; Engel J; Hermann R
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progressive decrease of melatonin production over consecutive days of simulated night work.
    Dumont M; Paquet J
    Chronobiol Int; 2014 Dec; 31(10):1231-8. PubMed ID: 25222345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.